New MRI Liver Contrast Agent Primovist(R) Approved in EU.
"We are excited about the introduction of Primovist(R) to the European markets as it represents a new powerful tool for the radiologists", said Michael Rook, Head of Diagnostic Imaging at Schering AG. "Primovist(R) allows to simultaneously detect, locate and distinguish various types of liver lesions. In addition, with only one single injection, Primovist offers a cost effective and patient friendly method for diagnosing liver disease. By adding Primovist(R) to our imaging portfolio, we further emphasize our position as a true innovator and as the world's leading company in the field of MRI contrast media."
The Swedish registration for Primovist(R) was granted in March of this year and the product was successfully launched in Sweden in September. Based on the Swedish approval European marketing authorization was granted after completion of a mutual recognition procedure with Sweden as Reference Member State in 25 European countries exept France and Denmark. Following its approval, Primovist(R) will be rolled-out in the major European markets, starting in Germany in the first quarter of 2005.
In its clinical development Primovist(R) has proven distinct diagnostic efficacy and an excellent safety profile. Primovist(R) has been submitted for approval also in Japan, where liver examinations are particularly frequent.
Primovist(R) is chemically related to Schering's Magnevist(R) (Gd-DTPA) which is the world's leading MRI contrast agent. Like Magnevist(R) it brightens the signal of T1-weighted MR images.
Owing to its structural properties, Primovist(R) is specifically taken up by liver cells (hepatocytes), thus enhancing healthy liver tissue (parenchymal enhancement). Lesions with no or minimal hepatocyte function (cysts, metastases, the majority of hepatocellular carcinomas) will remain unenhanced and will therefore be more readily detected and localized. Primovist(R) furthermore provides useful diagnostic information at the time immediately after contrast administration (dynamic imaging) and thus also supports lesion characterization (i.e. distinction of different types of liver lesions).
Primovist(R) is supplementary to the previously introduced Resovist(R). Whereas Resovist(R) is first of all used for detection of small liver lesions, e.g. for pre-surgical examinations, the additional strength of Primovist(R) lies particularly in the combination of parenchymal and dynamic imaging, the latter providing useful information for the characterization of liver lesions.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Diagnostics&Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Business: Dr Friedrich von Heyl, T: +49-30-468-152-96; email@example.com
Investor Relations: Peter Vogt, T: +49-30-468-128-38, firstname.lastname@example.org
Pharma Communication: Dr Claudia Schmitt, T: +49-30-468-158-05, email@example.com
Your contacts in the US:
Investor Relations: Joanne Marion, T: +1-973-487-2164, firstname.lastname@example.org
Find additional information at: www.schering.de/eng
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
CONTACT: Your contact: Business: Dr Friedrich von Heyl, T: +49-30-468-152-96; email@example.com. Investor Relations: Peter Vogt, T: +49-30-468-128-38, firstname.lastname@example.org. Pharma Communication: Dr Claudia Schmitt, T: +49-30-468-158-05, email@example.com. Your contacts in the US: Investor Relations: Joanne Marion, T: +1-973-487-2164, firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 30, 2004|
|Previous Article:||Acambis Appoints Dr Randal Chase as Non-Executive Director.|
|Next Article:||Signing of the Definitive Agreement Between Gold Fields Limited and Iamgold Corporation.|